0208080893 [email protected]
Providers / Bioss Primary Conjugated Antibodies. ALEXA FLUOR / TIFA Antibody, ALEXA FLUOR 594

Description:

Size: 100ul

Catalog no.: bs-13669R-A594

Price: 380 EUR

Get for 380 EUR on Gentaur.com

/ningbo-assets-bio/graphics/prods/bigs/bigs6.jpg

Product details

Target Antigen

TIFA

Modification Site

None

Crossreactivity

Human

French translation

anticorps

Tested applications

IF(IHC-P)

Modification

Unmodified

Clonality

Polyclonal

Excitation emission

590nm/617nm

Concentration

1ug per 1ul

Conjugated with

ALEXA FLUOR® 594

Conjugated

Alexa conjugate 1

Recommended dilutions

IF(IHC-P)(1:50-200)

Clone

Polyclonal antibody

Purification

Purified by Protein A.

Conjugation

Alexa Fluor,ALEXA FLUOR® 594

Category

Conjugated Primary Antibodies

Also known as

Anti-TIFA PAb ALEXA FLUOR 594

Host Organism

Rabbit (Oryctolagus cuniculus)

Specificity

This is a highly specific antibody against TIFA.

Long name

TIFA Polyclonal Antibody, ALEXA FLUOR 594 Conjugated

Cross-reactive species details

Due to limited amount of testing and knowledge, not every possible cross-reactivity is known.

Source

This antibody was obtained by immunization of the host with KLH conjugated synthetic peptide derived from human TIFA

Storage conditions

Store this antibody in aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Keep refrigerated at 2 to 8 degrees Celcius for up to one year.

Properties

For facs or microscopy Alexa 1 conjugate.If you buy Antibodies supplied by Bioss Primary Conjugated Antibodies. ALEXA FLUOR they should be stored frozen at - 24°C for long term storage and for short term at + 5°C.

Background of the antigen

Adapter protein which mediates the IRAK1 and TRAF6 interaction following IL-1 stimulation, resulting in the downstream activation of NF-kappa-B and AP-1 pathways. Induces the oligomerization and polyubiquitination of TRAF6, which leads to the activation of TAK1 and IKK through a proteasome-independent mechanism.

Synonyms

Putative MAPK activating protein PM14; Putative MAPK-activating protein PM14; Putative NF kappa B activating protein 20; Putative NF-kappa-B-activating protein 20; T2BP; TA; TA_HUMAN; TRAF interacting protein with FHA domain containing protein A; TRAF-interacting protein with FHA domain-containing protein A; TRAF2 binding protein; TRAF2-binding protein.